Concourse Financial Group Securities, Inc. Renovo Rx, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.67 Billion
Q4 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share
Q4 2024 Feb 13, 2025	BUY	$0.9 - $1.43 $0 - $0
Q3 2024 Oct 10, 2024	BUY	$0.96 - $1.29 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$1.02 - $1.46 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$1.02 - $1.98 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$0.6 - $2.29 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$1.3 - $2.3 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$1.3 - $2.3 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$1.85 - $3.21 $0 - $0
Q1 2023 May 15, 2023	BUY	$2.51 - $5.25 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$1.65 - $2.35 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$1.84 - $2.79 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$1.52 - $2.99 $0 - $0
Q1 2022 May 09, 2022	BUY	$2.87 - $4.9 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$4.72 - $8.5 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$6.04 - $16.02 $0 - $0

Others Institutions Holding RNXT

# of Institutions

Shares Held

1.97M

Call Options Held

Put Options Held

View Full List

About RenovoRx, Inc.

Ticker RNXT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,066,860
Market Cap $9.43M
Description
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, In...

More about RNXT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account